Stifel Maintains Buy on Apellis Pharmaceuticals, Raises Price Target to $65
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Annabel Samimy has maintained a 'Buy' rating on Apellis Pharmaceuticals (NASDAQ:APLS) and raised the price target from $60 to $65.
August 29, 2023 | 4:52 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Stifel analyst Annabel Samimy has maintained a 'Buy' rating on Apellis Pharmaceuticals and raised the price target from $60 to $65. This could potentially lead to an increase in the stock's price.
The 'Buy' rating maintained by Stifel indicates a positive outlook for Apellis Pharmaceuticals. The increase in the price target from $60 to $65 suggests that the analyst believes the stock has potential for growth, which could lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100